Effects of preinduced Candida-specific systemic cell-mediated immunity on experimental vaginal candidiasis
- PMID: 8112837
- PMCID: PMC186220
- DOI: 10.1128/iai.62.3.1032-1038.1994
Effects of preinduced Candida-specific systemic cell-mediated immunity on experimental vaginal candidiasis
Abstract
It has been postulated that systemic cell-mediated immunity (CMI) is an important host defense factor against recurrent vaginal infections caused by Candida albicans. Using an estrogen-dependent murine model of vaginal candidiasis, we have previously shown that mice inoculated vaginally with C. albicans acquire a persistent vaginal infection and develop Candida-specific Th1-type systemic CMI. In the present study, experimental vaginitis was monitored in the presence of preinduced systemic Candida-specific CMI. Mice immunized systemically with C. albicans culture filtrate antigens (CaCF) in complete Freund's adjuvant (CFA) had Th1-type reactivity similar to that of vaginally infected mice. CaCF given to mice intravenously induced Candida-specific suppressor T (Ts) cells. Mice preimmunized with CaCF-CFA and given a vaginal inoculum of C. albicans had positive delayed-type hypersensitivity (DTH) reactivity from the time of vaginal inoculation through 4 weeks. Conversely, mice infected in the presence of Ts cells had significantly reduced DTH responses throughout the 4-week period in comparison with naive infected mice. However, the presence of Th1-type Candida-specific DTH cells or Ts cells, either induced in mice prior to vaginal inoculation or adoptively transferred at the time of inoculation, had no effect on the vaginal Candida burden through 4 weeks of infection. A similar lack of effects was obtained in animals with lower Candida population levels resulting from a reduction in or absence of exogenous estrogen. These results suggest that systemic Th1-type CMI demonstrable with CaCF is unrelated to protective events at the level of the vaginal mucosa.
Similar articles
-
Mice immunized by primary vaginal Candida albicans infection develop acquired vaginal mucosal immunity.Infect Immun. 1995 Feb;63(2):547-53. doi: 10.1128/iai.63.2.547-553.1995. Infect Immun. 1995. PMID: 7822020 Free PMC article.
-
Candida-specific Th1-type responsiveness in mice with experimental vaginal candidiasis.Infect Immun. 1993 Oct;61(10):4202-7. doi: 10.1128/iai.61.10.4202-4207.1993. Infect Immun. 1993. PMID: 8406809 Free PMC article.
-
Candida-specific cell-mediated immunity is demonstrable in mice with experimental vaginal candidiasis.Infect Immun. 1993 May;61(5):1990-5. doi: 10.1128/iai.61.5.1990-1995.1993. Infect Immun. 1993. PMID: 8097493 Free PMC article.
-
Immunity to Candida.Oral Dis. 2002;8 Suppl 2:69-75. doi: 10.1034/j.1601-0825.2002.00015.x. Oral Dis. 2002. PMID: 12164664 Review.
-
The protective immune response against vaginal candidiasis: lessons learned from clinical studies and animal models.Int Rev Immunol. 2002 Nov-Dec;21(6):515-48. doi: 10.1080/08830180215015. Int Rev Immunol. 2002. PMID: 12650240 Review.
Cited by
-
Immunopathogenesis of recurrent vulvovaginal candidiasis.Clin Microbiol Rev. 1996 Jul;9(3):335-48. doi: 10.1128/CMR.9.3.335. Clin Microbiol Rev. 1996. PMID: 8809464 Free PMC article. Review.
-
Mice immunized by primary vaginal Candida albicans infection develop acquired vaginal mucosal immunity.Infect Immun. 1995 Feb;63(2):547-53. doi: 10.1128/iai.63.2.547-553.1995. Infect Immun. 1995. PMID: 7822020 Free PMC article.
-
Patterns of Expression of Vaginal T-Cell Activation Markers during Estrogen-Maintained Vaginal Candidiasis.Allergy Asthma Clin Immunol. 2008 Dec 15;4(4):157-63. doi: 10.1186/1710-1492-4-4-157. Epub 2008 Dec 15. Allergy Asthma Clin Immunol. 2008. PMID: 20525139 Free PMC article.
-
Local production of chemokines during experimental vaginal candidiasis.Infect Immun. 1999 Nov;67(11):5820-6. doi: 10.1128/IAI.67.11.5820-5826.1999. Infect Immun. 1999. PMID: 10531235 Free PMC article.
-
Vaginal T lymphocyte population kinetics during experimental vaginal candidosis: evidence for a possible role of CD8+ T cells in protection against vaginal candidosis.Clin Exp Immunol. 2003 Jan;131(1):26-33. doi: 10.1046/j.1365-2249.2003.02032.x. Clin Exp Immunol. 2003. PMID: 12519382 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources